Investigational drug · Phase 3
Surzebiclimab
Also called: BGB-A425
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
3
Any phase or sponsor naming "Surzebiclimab"
First trial start
2018
Nov 13, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Surzebiclimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
- HNSCC for Phase 2 Dose Expansion
- NSCLC for Phase 2 Dose Expansion
- Advanced Malignancies
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Surzebiclimab" as an intervention, largest first.
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell CarcinomaPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05909904 · 160 participants · Start Aug 2, 2023 · Primary completion Jun 17, 2025
Drug: Tislelizumab; BGB-A425 and 1 more · For: Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer
Sites: Los Angeles, California; Stanford, California; Lone Tree, Colorado · 73 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03744468 · 147 participants · Start Nov 13, 2018 · Primary completion Feb 6, 2025
Drug: Surzebiclimab; Tislelizumab and 1 more · For: Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in; HNSCC for Phase 2 Dose Expansion; NSCLC for Phase 2 Dose Expansion
Sites: Orange, California; Aurora, Colorado; Chicago, Illinois · 40 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.